Iovance Biotherapeutics Inc. [NASDAQ: IOVA] stock went on a downward path that fall over -5.22% on Friday, amounting to a one-week price decrease of less than -8.58%. The company report on March 16, 2021 that Iovance Biotherapeutics Appoints Igor Bilinsky as Chief Operating Officer.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the appointment of Igor Bilinsky, Ph.D., as Chief Operating Officer, effective today. Dr. Bilinsky brings more than 20 years of biotechnology industry experience as a senior executive and consultant, including public companies.
“I am pleased to welcome Igor to Iovance and look forward to his contributions while we advance our TIL cell therapy pipeline,” stated Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics. “Through his experience in several senior leadership roles across multiple functional areas, Igor has led multiple teams across different companies, including internal manufacturing, and created significant shareholder value. These capabilities are important to Iovance in furthering our leadership in TIL cell therapy development, manufacturing and potential commercialization.”.
Over the last 12 months, IOVA stock dropped by -10.29%. The average equity rating for IOVA stock is currently 1.70, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $4.45 billion, with 138.30 million shares outstanding and 135.58 million shares in the current float. Compared to the average trading volume of 1.50M shares, IOVA stock reached a trading volume of 3710807 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Iovance Biotherapeutics Inc. [IOVA]:
H.C. Wainwright have made an estimate for Iovance Biotherapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 08, 2021. The new note on the price target was released on December 15, 2020, representing the official price target for Iovance Biotherapeutics Inc. stock.
The Average True Range (ATR) for Iovance Biotherapeutics Inc. is set at 2.74 The Price to Book ratio for the last quarter was 6.04, with the Price to Cash per share for the same quarter was set at 4.06.
IOVA Stock Performance Analysis:
Iovance Biotherapeutics Inc. [IOVA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.58. With this latest performance, IOVA shares dropped by -21.47% in over the last four-week period, additionally sinking by -9.62% over the last 6 months – not to mention a drop of -10.29% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IOVA stock in for the last two-week period is set at 30.96, with the RSI for the last a single of trading hit 28.43, and the three-weeks RSI is set at 33.36 for Iovance Biotherapeutics Inc. [IOVA]. The present Moving Average for the last 50 days of trading for this stock 40.98, while it was recorded at 30.42 for the last single week of trading, and 36.75 for the last 200 days.
Insight into Iovance Biotherapeutics Inc. Fundamentals:
Iovance Biotherapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.60 and a Current Ratio set at 11.60.
IOVA Stock EPS
With the latest financial reports released by the company, Iovance Biotherapeutics Inc. posted -0.55/share EPS, while the average EPS was predicted by analysts to be reported at -0.51/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -7.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IOVA.
Iovance Biotherapeutics Inc. [IOVA] Insider Position Details
There are presently around $4,263 million, or 99.22% of IOVA stock, in the hands of institutional investors. The top three institutional holders of IOVA stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 15,297,822, which is approximately 93.562% of the company’s market cap and around 0.77% of the total institutional ownership; VANGUARD GROUP INC, holding 11,865,382 shares of the stock with an approximate value of $340.18 million in IOVA stocks shares; and PERCEPTIVE ADVISORS LLC, currently with $262.8 million in IOVA stock with ownership of nearly -9.115% of the company’s market capitalization.
142 institutional holders increased their position in Iovance Biotherapeutics Inc. [NASDAQ:IOVA] by around 23,691,684 shares. Additionally, 134 investors decreased positions by around 14,719,110 shares, while 29 investors held positions by with 110,271,384 shares. The mentioned changes placed institutional holdings at 148,682,178 shares, according to the latest SEC report filing. IOVA stock had 59 new institutional investments in for a total of 3,549,071 shares, while 39 institutional investors sold positions of 3,565,435 shares during the same period.